# US 2026/0144794 A1 · Therapeutic compositions and methods for treating cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0144794 A1
- Document ID: US20260144794A1
- Status: Published application
- Kind: A1
- Application number: 19/444,002
- Filed: 2026-01-08
- Published: 2026-05-28
- Earliest claimed: 2019-06-21
- Assignees: Pattern Computer, Inc.
- Applicants: Pattern Computer, Inc.
- Inventors: Nidhi SINGH; Meenakshi VENKATASUBRAMANIAN; Quinn JACKSON
- Web page: https://patentgrep.com/patent/US20260144794A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/52: Purines, e.g. adenine
- A61K 31/69: Boron compounds
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides therapeutic combinations, which provide a synergistic effect in treating a cancer. The present disclosure provides methods of treatment including administration of the combinations, and uses of the combinations, e.g., for treatment of cancer.

## Claims

### Claim at position 1

1-38. (canceled)

### Claim 39

A method of treating triple negative breast cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ribociclib and a therapeutically effective amount of dabrafenib, wherein the ribociclib and the dabrafenib are provided in synergistically effective amounts.

### Claim 40 (depends on 39)

The method of claim 39, wherein the triple negative breast cancer is basal-like breast cancer.

### Claim 41 (depends on 39)

The method of claim 39, wherein the molar ratio of the ribociclib to the dabrafenib is between 2:1 and 1:2.

### Claim 42 (depends on 40)

The method of claim 40, wherein the molar ratio of the ribociclib to the dabrafenib is between 2:1 and 1:2.

### Claim 43 (depends on 39)

The method of claim 39, wherein the administering of the ribociclib and the dabrafenib is at least five times more effective at killing malignant cells than it is at killing non-malignant cells.

### Claim 44 (depends on 40)

The method of claim 40, wherein the administering of the ribociclib and the dabrafenib is at least five times more effective at killing malignant cells than it is at killing non-malignant cells.

### Claim 45 (depends on 41)

The method of claim 41, wherein the administering of the ribociclib and the dabrafenib is at least five times more effective at killing malignant cells than it is at killing non-malignant cells.

### Claim 46 (depends on 42)

The method of claim 42, wherein the administering of the ribociclib and the dabrafenib is at least five times more effective at killing malignant cells than it is at killing non-malignant cells.

### Claim 47 (depends on 39)

The method of claim 39, wherein the administering of the ribociclib and the dabrafenib is simultaneous.

### Claim 48 (depends on 40)

The method of claim 40, wherein the administering of the ribociclib and the dabrafenib is sequential.
